Daniel D. Karp

18.8k total citations · 4 hit papers
217 papers, 9.4k citations indexed

About

Daniel D. Karp is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Daniel D. Karp has authored 217 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Oncology, 88 papers in Pulmonary and Respiratory Medicine and 70 papers in Molecular Biology. Recurrent topics in Daniel D. Karp's work include Lung Cancer Treatments and Mutations (49 papers), Cancer Genomics and Diagnostics (31 papers) and Colorectal Cancer Treatments and Studies (22 papers). Daniel D. Karp is often cited by papers focused on Lung Cancer Treatments and Mutations (49 papers), Cancer Genomics and Diagnostics (31 papers) and Colorectal Cancer Treatments and Studies (22 papers). Daniel D. Karp collaborates with scholars based in United States, China and Netherlands. Daniel D. Karp's co-authors include Philip Bonomi, Mark S. Huberman, R. Lotan, P. Santabárbara, Abraham Chachoua, James R. Rigas, Lisa A. Hammond, Román Pérez-Soler, Eric K. Rowinsky and Everett E. Vokes and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Daniel D. Karp

210 papers receiving 9.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

2000 1.1k citations Frank V. Fossella, Vincent A. Miller et al. Journal of Clinical Oncology profile →
Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and Neck

1990 1.1k citations Daniel D. Karp et al. profile →
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

2004 893 citations Daniel D. Karp et al. Journal of Clinical Oncology profile →
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer

2003 862 citations Daniel D. Karp et al. profile →

Peers

Countries citing papers authored by Daniel D. Karp

Since Specialization

Citations

This map shows the geographic impact of Daniel D. Karp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel D. Karp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel D. Karp more than expected).

Fields of papers citing papers by Daniel D. Karp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel D. Karp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel D. Karp. The network helps show where Daniel D. Karp may publish in the future.

Co-authorship network of co-authors of Daniel D. Karp

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel D. Karp. A scholar is included among the top collaborators of Daniel D. Karp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel D. Karp. Daniel D. Karp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Supplemental Data for A Phase II Study of Talazoparib Tosylate in Advanced Cancer Patients with Somatic and Germline (Not Breast or Ovarian Cancer) Alterations of BRCA1/2, Mutations/Deletions/Amplification in Other Homologous Recombination Repair Pathway Genes and PTEN or PTEN loss 2024 ·Sarina A. Piha‐Paul, Chieh Tseng, Cheuk Hong Leung, (unknown), Daniel D. Karp, Vivek Subbiah, David S. Hong, Siqing Fu, Aung Naing, Jordi Rodón, Milind Javle, Jaffer A. Ajani, Kanwal Raghav, Neeta Somaiah, Gordon B. Mills, Apostolia M. Tsimberidou, Xiaofeng Zheng, Ken Chen, Funda Meric‐Bernstam	1
2	A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Mohamed A. Gouda, (unknown), Aung Naing, Ecaterina E. Dumbrava, David S. Hong, Ying Yuan, Peiying Yang, Alan L. Myers, Yulong Liang, Jing Ping, Daniel D. Karp, Apostolia M. Tsimberidou, Jordi Rodón, Timothy A. Yap, Sarina A. Piha‐Paul, Funda Meric‐Bernstam, Siqing Fu	1
3	Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations 2024 ·npj Precision Oncology ·Sarina A. Piha‐Paul, Chieh Tseng, Cheuk Hong Leung, Ying Yuan, Daniel D. Karp, Vivek Subbiah, David S. Hong, Siqing Fu, Aung Naing, Jordi Rodón, Milind Javle, Jaffer A. Ajani, Kanwal Raghav, Neeta Somaiah, Gordon B. Mills, Apostolia M. Tsimberidou, Xiaofeng Zheng, Ken Chen, Funda Meric‐Bernstam	4
4	Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer 2023 ·SHILAP Revista de lepidopterología ·Ji Son, Heather Lin, Siqing Fu, Amadeo B. Biter, Ecaterina E. Dumbrava, Daniel D. Karp, Aung Naing, Shubham Pant, Sarina A. Piha‐Paul, Jordi Rodón, Vivek Subbiah, Apostolia M. Tsimberidou, Timothy A. Yap, Michael Frumovitz, Amir A. Jazaeri, Pedro T. Ramírez, Shannon N. Westin, Ying Yuan, Funda Meric‐Bernstam, David S. Hong	1
5	A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors 2023 ·The Oncologist ·Blessie Elizabeth Nelson, Apostolia M. Tsimberidou, Xueyao Fu, Siqing Fu, Vivek Subbiah, Anil K. Sood, Jordi Rodón, Daniel D. Karp, George R. Blumenschein, Scott Kopetz, Shubham Pant, Sarina A. Piha‐Paul	6
6	Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non–small cell lung cancer 2023 ·Cancer ·Mehmet Altan, (unknown), Denái R. Milton, Bülent Yılmaz, Yanyan Tian, Frank V. Fossella, Frank E. Mott, George R. Blumenschein, Bettzy Stephen, Daniel D. Karp, Funda Meric‐Bernstam, John V. Heymach, Aung Naing	6
7	Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies 2023 ·Cancer ·(unknown), Jibran Ahmed, Bettzy Stephen, Sarina A. Piha‐Paul, Daniel D. Karp, Abdulrazzak Zarifa, Siqing Fu, David S. Hong, Jordi Rodón, Timothy A. Yap, Apostolia M. Tsimberidou, Anas Alshawa, Ecaterina E. Dumbrava, (unknown), Juhee Song, Funda Meric‐Bernstam, Amir A. Jazaeri, Aung Naing	11
8	Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification 2022 ·Journal of Clinical Oncology ·Siqing Fu, Shuyang Yao, Yuan Yuan, Rebecca A. Previs, Anthony Elias, Richard D. Carvajal, Thomas J. George, Ying Yuan, (unknown), Shannon N. Westin, (unknown), Ecaterina E. Dumbrava, Daniel D. Karp, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Jordi Rodón, Naoko Takebe, Karen H. Lu, Khandan Keyomarsi, Funda Meric‐Bernstam	50
9	Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours 2022 ·EClinicalMedicine ·Daniel D. Karp, D. Ross Camidge, J. Infante, Tyler D. Ames, (unknown), José Jimeno, Alan H. Bryce	25
10	Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers 2022 ·JCO Precision Oncology ·Mohamed A. Gouda, Helen J. Huang, Sarina A. Piha‐Paul, (unknown), Daniel D. Karp, Siqing Fu, Aung Naing, Vivek Subbiah, Shubham Pant, Derek Dustin, Apostolia M. Tsimberidou, David S. Hong, Jordi Rodón, Funda Meric‐Bernstam, Filip Jankú	28
11	Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor 2021 ·Clinical Cancer Research ·David S. Hong, Kathleen N. Moore, Johanna C. Bendell, Daniel D. Karp, Judy S. Wang, Susanna V. Ulahannan, Suzanne F. Jones, Wenjuan Wu, Gregory P. Donoho, Yan Ding, Andrew Capen, (unknown), Aimee Bence Lin, Manish R. Patel	37
12	Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial 2021 ·Investigational New Drugs ·Andrew W. Hahn, Jad Chahoud, Matthew T. Campbell, Daniel D. Karp, Jennifer Wang, Bettzy Stephen, Shi‐Ming Tu, Curtis A. Pettaway, Aung Naing	37
13	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials 2018 ·Lung Cancer ·(unknown), Kenneth R. Hess, Roman Groisberg, David S. Hong, Aung Naing, Sarina A. Piha‐Paul, Filip Jankú, Siqing Fu, Apostolia M. Tsimberidou, Shubham Pant, Daniel D. Karp, Shuang Liu, Ming Sun, John V. Heymach, George R. Simon, Funda Meric‐Bernstam, Vivek Subbiah	27
14	A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement 2018 ·Cancer Chemotherapy and Pharmacology ·Elena Fountzilas, (unknown), Filip Jankú, Siqing Fu, Daniel D. Karp, Aung Naing, Vivek Subbiah, David S. Hong, Sarina A. Piha‐Paul, David Vining, Apostolia M. Tsimberidou	5
15	Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study 2018 ·Journal of Medical Internet Research ·Goldy C. George, (unknown), (unknown), Sarina A. Piha‐Paul, Vivek Subbiah, Siqing Fu, Daniel D. Karp, Shubham Pant, (unknown), Kenneth R. Hess, Charles S. Cleeland, Elmer V. Bernstam, Funda Meric‐Bernstam, David S. Hong	16
16	Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act 2017 ·Clinical Cancer Research ·Kenneth L. Kehl, (unknown), Siqing Fu, Goldy C. George, Kenneth R. Hess, Filip Jankú, Daniel D. Karp, Shumei Kato, (unknown), Razelle Kurzrock, Aung Naing, Shubham Pant, Sarina A. Piha‐Paul, Vivek Subbiah, Apostolia M. Tsimberidou, David S. Hong	4
17	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells 2016 ·Clinical Cancer Research ·Chad Tang, James W. Welsh, Patricia M. de Groot, Erminia Massarelli, Joe Y. Chang, Kenneth R. Hess, Sreyashi Basu, Michael A. Curran, Maria E. Cabanillas, Vivek Subbiah, Siqing Fu, Apostolia M. Tsimberidou, Daniel D. Karp, Daniel R. Gomez, Adi Diab, Ritsuko Komaki, John V. Heymach, Padmanee Sharma, Aung Naing, David S. Hong	251
18	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics 2016 ·Molecular Cancer Therapeutics ·Jennifer J. Wheler, Filip Jankú, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel D. Karp, Gerald S. Falchook, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Roosevelt Anderson, (unknown), Vincent A. Miller, Roman Yelensky, J. Jack Lee, David S. Hong, Razelle Kurzrock	73
19	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study 2016 ·Cancer Research ·Jennifer J. Wheler, Filip Jankú, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel D. Karp, Gerald S. Falchook, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Roosevelt Anderson, (unknown), Vincent A. Miller, Roman Yelensky, J. Jack Lee, David S. Hong, Razelle Kurzrock	149
20	Clinical trial of combined therapy with adriamycin and cis-dichlorodiammineplatinum(II). 1977 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·(unknown), L. Herbert Maurer, R. Jackson Forcier, (unknown), (unknown), Daniel D. Karp, (unknown), O. Ross McIntyre, Christopher J. Bean	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact